Dataset Information

Acetylome Profiling Reveals the Endogenous Substrates of HDAC6

ABSTRACT: HDAC6 inhibitors are novel targeted therapies showing good clinical response in a variety of different malignancies. However, their use and farther development is hampered by the limited knowledge regarding what are the endogenous substrates of HDAC6 enzyme. Here we plan to complete acetylome profiling of HAP1 cells with and without HDAC6 knockout to identify which are the HDAC6 substrates and what are the differences between the wildtype and HDAC6-KO cells.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Yuxin Li

LAB HEAD: Junmin Peng

PROVIDER: PXD026010 | Pride | 2022-11-09

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	checksum.txt	Txt
	yu3grp_082019_AcTMT_f01a.1.pepXML	Pepxml
	yu3grp_082019_AcTMT_f01a.raw	Raw
	yu3grp_082019_AcTMT_f01b.1.pepXML	Pepxml
	yu3grp_082019_AcTMT_f01b.raw	Raw

Items per page:

1 - 5 of 51

Publications

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.

Zeleke Tizita Z TZ Pan Qingfei Q Chiuzan Codruta C Onishi Maika M Li Yuxin Y Tan Haiyan H Alvarez Mariano J MJ Honan Erin E Yang Min M Chia Pei Ling PL Mukhopadhyay Partha P Kelly Sean S Wu Ruby R Fenn Kathleen K Trivedi Meghna S MS Accordino Melissa M Crew Katherine D KD Hershman Dawn L DL Maurer Matthew M Jones Simon S High Anthony A Peng Junmin J Califano Andrea A Kalinsky Kevin K Yu Jiyang J Silva Jose J

Nature cancer 20221230 2

Inhibiting individual histone deacetylase (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through preclinical studies, we demonstrated that the sensitivity to the leading HDAC6 inhibitor (HDAC6i) ricolinstat can be predicted by a computational network-based algorithm (HDAC6 score). Analysis of ~3,000 human breast cancers (BCs) showed that ~30% of them could benefice from HDAC6i therapy. Thus, we designed a phase 1b dose-escalation clinical trial to eva ...[more]

PMID: 36585452

Dataset Information

Acetylome Profiling Reveals the Endogenous Substrates of HDAC6

Dataset's files

Publications

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Hdac6 regulates Tip60-p400 function in stem cells (sequencing)
2013-11-20 | E-GEOD-42209 | biostudies-arrayexpress

HDAC6 Inhibition Disrupts HDAC6-P300 Interaction Reshaping the Cancer Chromatin Landscape (ChIP-Seq)
2024-08-19 | GSE273645 | GEO

HDAC6 Inhibition Disrupts HDAC6-P300 Interaction Reshaping the Cancer Chromatin Landscape (ATAC-Seq)
2024-08-19 | GSE273644 | GEO

HDAC6 and HSP90 control the functions of Foxp3+ T regulatory cells
2011-05-01 | E-GEOD-27896 | biostudies-arrayexpress

HDAC6 overexpression effect on mouse ESCs
2016-12-01 | GSE81710 | GEO

Hdac6 is a stem-cell specific modulator of Tip60-p400 function (gene expression)
2013-11-20 | E-GEOD-42208 | biostudies-arrayexpress

ARID1A-mutated ovarian cancers depend on HDAC6 activity
2017-07-14 | GSE84405 | GEO

HDAC6 interacting proteins under different stresses
2023-10-17 | PXD038816 | Pride

Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat [array]
2023-02-09 | GSE180606 | GEO

Hdac6 regulates Tip60-p400 function in stem cells (sequencing)
2013-11-20 | GSE42209 | GEO